Document is current
Any future updates will be listed below
-
Authors
Lago, Tiffany R.
Brownstein, Michael J.
Page, Emily
Beydler, Emily
Manbeck, Adrienne
Beale, Alexis
Roberts, Camille
Balderston, Nicholas
Damiano, Eve
Pineles, Suzanne L.
Simon, Neal
Ernst, Monique
Grillon, Christian
-
Funding
Funding for this research was provided by:
National Institutes of Health (ZIAMH002798)
Azevan Pharmaceuticals Inc
- License Information
-
More Information
Article History
Received: 26 August 2020
Accepted: 26 April 2021
First Online: 10 May 2021
Declaration
:
: T.L., E.P., E.B., A.M., A.B., C.R., N.B., E.D., S.P., M.E., and C.G. have nothing to disclose. M.B. and N.S. serve as officers at Azevan Pharmaceuticals Inc. and hold equity in the Company. Azevan Pharmaceuticals Inc. provided SRX246 and placebo without charge and funded analysis of plasma samples for drug content. T.L., E.P., E.B., A.M., A.B., C.R., N.B., S.P., M.E., and C.G. did not receive any payment or other benefits from Azevan Pharmaceuticals Inc.
